{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:30:03Z","timestamp":1780471803489,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10238-015-0370-5","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T15:23:19Z","timestamp":1434640999000},"page":"407-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of cilostazol for the treatment of Raynaud\u2019s phenomenon in systemic sclerosis patients"],"prefix":"10.1007","volume":"16","author":[{"given":"Simone","family":"Negrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Span\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Penza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rollando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Indiveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Filaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Puppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,19]]},"reference":[{"key":"370_CR1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989\u20132003.","journal-title":"N Engl J Med"},{"key":"370_CR2","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1136\/bmj.e289","volume":"344","author":"B Goundry","year":"2012","unstructured":"Goundry B, Bell L, Langtree M, Moorthy A. Diagnosis and management of Raynaud\u2019s phenomenon. BMJ. 2012;344:e289.","journal-title":"BMJ"},{"key":"370_CR3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","volume":"13","author":"M Prete","year":"2014","unstructured":"Prete M, Fatone MC, Favoino E, Perosa F. Raynaud\u2019s phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014;13:655\u201367.","journal-title":"Autoimmun Rev"},{"key":"370_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/VHRM.S5255","volume":"6","author":"M Baumhakel","year":"2010","unstructured":"Baumhakel M, Bohm M. Recent achievements in the management of Raynaud\u2019s phenomenon. Vasc Health Risk Manag. 2010;6:207\u201314.","journal-title":"Vasc Health Risk Manag"},{"key":"370_CR5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/VHRM.S4551","volume":"6","author":"TL Levien","year":"2010","unstructured":"Levien TL. Advances in the treatment of Raynaud\u2019s phenomenon. Vasc Health Risk Manag. 2010;6:167\u201377.","journal-title":"Vasc Health Risk Manag"},{"key":"370_CR6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis. 2009;68:620\u20138.","journal-title":"Ann Rheum Dis"},{"key":"370_CR7","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00296-011-1878-y","volume":"32","author":"P Caramaschi","year":"2012","unstructured":"Caramaschi P, Dalla Gassa A, Prati D, et al. Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost. Rheumatol Int. 2012;32:1933\u20138.","journal-title":"Rheumatol Int"},{"issue":"1","key":"370_CR8","first-page":"CD008076","volume":"32","author":"AK Kamal","year":"2011","unstructured":"Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011;(1):CD008076.","journal-title":"Cochrane Database Syst Rev"},{"key":"370_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2459\/JCM.0b013e3283439746","volume":"12","author":"N Kanlop","year":"2011","unstructured":"Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown). 2011;12:88\u201395.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"370_CR10","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1517\/14656566.9.15.2683","volume":"9","author":"L Pearce","year":"2008","unstructured":"Pearce L, Ghosh J, Counsell A, Serracino-Inglott F. Cilostazol and peripheral arterial disease. Expert Opin Pharmacother. 2008;9:2683\u201390.","journal-title":"Expert Opin Pharmacother"},{"key":"370_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2011.09.048","volume":"220","author":"DF Geng","year":"2012","unstructured":"Geng DF, Deng J, Jin DM, Wu W, Wang JF. Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;220:177\u201383.","journal-title":"Atherosclerosis"},{"key":"370_CR12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jvs.2013.11.096","volume":"59","author":"CJ Warner","year":"2014","unstructured":"Warner CJ, Greaves SW, Larson RJ, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014;59:1607\u201314.","journal-title":"J Vasc Surg"},{"key":"370_CR13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","volume":"92","author":"S Rajagopalan","year":"2003","unstructured":"Rajagopalan S, Pfenninger D, Somers E, et al. Effects of cilostazol in patients with Raynaud\u2019s syndrome. Am J Cardiol. 2003;92:1310\u20135.","journal-title":"Am J Cardiol"},{"key":"370_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","unstructured":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"370_CR15","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202\u20135.","journal-title":"J Rheumatol"},{"key":"370_CR16","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","volume":"46","author":"PA Merkel","year":"2002","unstructured":"Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon. Arthritis Rheum. 2002;46:2410\u201320.","journal-title":"Arthritis Rheum"},{"key":"370_CR17","first-page":"112","volume":"58","author":"G Montagna La","year":"2006","unstructured":"La Montagna G, Cuomo G, Chiarolanza I, Ruocco L. Valentini G [HAQ-DI italian version in systemic sclerosis]. Reumatismo. 2006;58:112\u20135.","journal-title":"Reumatismo"},{"key":"370_CR18","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","volume":"40","author":"VD Steen","year":"1997","unstructured":"Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40:1984\u201391.","journal-title":"Arthritis Rheum"},{"key":"370_CR19","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3899\/jrheum.091116","volume":"37","author":"D Rollando","year":"2010","unstructured":"Rollando D, Bezante GP, Sulli A, et al. Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol. 2010;37:1168\u201373.","journal-title":"J Rheumatol"},{"issue":"3","key":"370_CR20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","volume":"139","author":"D Fenoglio","year":"2011","unstructured":"Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol. 2011;139(3):249\u201357.","journal-title":"Clin Immunol"},{"issue":"3","key":"370_CR21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/iwj.12085","volume":"12","author":"S Franciscis De","year":"2015","unstructured":"De Franciscis S, Gallelli L, Battaglia L, et al. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. Int Wound J. 2015;12(3):250\u20133.","journal-title":"Int Wound J"},{"key":"370_CR22","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1186\/ar1454","volume":"7","author":"WU Kim","year":"2005","unstructured":"Kim WU, Min SY, Cho ML, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther. 2005;7:R71\u20139.","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-015-0370-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-015-0370-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-015-0370-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:37:42Z","timestamp":1559129862000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-015-0370-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s10238-015-0370-5","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,19]]}}}